ACR · ASX

Acrux Limited (ASX:ACR)

AU$0.034

 0.001 (3.03%)
ASX:Live
20/12/2024 04:10:10 PM
HALO Ords HALO Earnings Momentum HALO Consensus Value HALO Capital Efficiency GROWTH AUS +2
Consensus Score
/10
Recommend
Lock
Target Price
Lock
Deviation
Lock
Unlock Full Consensus Insights

ACR Overview

ACR Health Scores

Short Term

Mean Reversion

Neutral

Trend

Neutral

Event

Neutral

Halo Model

MQV

Very Strong

GARP

Very Strong

MQV Small

Neutral

Valuation

Value

Consensus

Momentum

Price

Strong

Earnings

Very Weak

Growth

Earnings

Weak

Dividends

Very Strong

Quality

Capital Efficiency

Very Weak

Balance Sheet

Very Strong

About ACR

Website

Acrux Limited

Telephone

61.3.8379.0100

Address

103-113 Stanley Street West Melbourne, Victoria (VIC) 3003

Description

Acrux Ltd. operates as a pooled development fund that invests in pharmaceutical businesses. The firm develops and commercializes pharmaceutical products using unique technology to administer drugs through the skin. Its products brands include AXIRON, ELLAVIE & EVAMIST and RECUVYRA. The company was founded by Ross Dobinson and Barrie Charles Finnin in 1998 and is headquartered in West Melbourne, Australia.

ACR Price Chart

Key Stats

Market Cap

AU$12.54M

PE

N/A

EV/EBITDA

N/A

Dividends Overview

DIV Yield

N/A

Franking

N/A

Ex Dividend Date (est.)

N/A

Market Data

52 weeks range

Low 0.03 - 0.1

Trade Value (12mth)

AU$7,057.00

1 week

3.12%

1 month

-26.67%

YTD

-32.65%

1 year

-26.67%

All time high

4.52

Key Fundamentals

EPS 3 yr Growth

-65.20%

EBITDA Margin

-158.40%

Operating Cashflow

-$4m

Free Cash Flow Return

-53.60%

ROIC

-72.20%

Interest Coverage

N/A

Quick Ratio

1.60

Other Data

Shares on Issue (Fully Dilluted)

290m

HALO Sector

Healthcare

Next Company Report Date

22-Aug-25

Ex Dividend Date (est.)

N/A

Next Dividend Pay Date (est.)

N/A

Reporting Currency

AUD

Short Sell (% of issue)

0.00

ACR Announcements

Latest Announcements

Date Announcements

19 December 24

Application for quotation of securities - ACR

×

Application for quotation of securities - ACR

19 December 24

Cleansing Notice

×

Cleansing Notice

19 December 24

Change in substantial holding

×

Change in substantial holding

17 December 24

Investor Deck update, SPP Closes 18 December 2024, 5pm

×

Investor Deck update, SPP Closes 18 December 2024, 5pm

16 December 24

Investor Webinar, Tuesday 17 December 2024 4pm AEDT

×

Investor Webinar, Tuesday 17 December 2024 4pm AEDT

13 December 24

Commercialisation of Nitroglycerin Ointment

×

Commercialisation of Nitroglycerin Ointment

12 December 24

Notification regarding unquoted securities - ACR

×

Notification regarding unquoted securities - ACR

12 December 24

Application for quotation of securities - ACR

×

Application for quotation of securities - ACR

12 December 24

Cleansing Notice

×

Cleansing Notice

12 December 24

Appendix 3Y - Brumley

×

Appendix 3Y - Brumley

12 December 24

Appendix 3Y Brooke

×

Appendix 3Y Brooke

12 December 24

Appendix 3Y - Dobinson

×

Appendix 3Y - Dobinson

12 December 24

Appendix 3Y - Oldham

×

Appendix 3Y - Oldham

12 December 24

Notification of cessation of securities - ACR

×

Notification of cessation of securities - ACR

12 December 24

Application for quotation of securities - ACR

×

Application for quotation of securities - ACR

12 December 24

Cleansing Notice

×

Cleansing Notice

06 December 24

Share Purchase Plan Offer Booklet

×

Share Purchase Plan Offer Booklet

05 December 24

Share Placement successfully concluded and SPP launched

×

Share Placement successfully concluded and SPP launched

05 December 24

Proposed issue of securities - ACR

×

Proposed issue of securities - ACR

05 December 24

Proposed issue of securities - ACR

×

Proposed issue of securities - ACR

05 December 24

Proposed issue of securities - ACR

×

Proposed issue of securities - ACR

05 December 24

Investor Presentation

×

Investor Presentation

05 December 24

Cleansing Notice

×

Cleansing Notice

04 December 24

FDA Approval - Nitroglycerin Ointment

×

FDA Approval - Nitroglycerin Ointment

03 December 24

Trading Halt

×

Trading Halt

Dividends

Key Stats

Ex Dividend Date (est.)

N/A

DIV Yield

N/A

Franking Level

N/A

DPSg

N/A

Quality Yield

Lock

Falling Divs over next 2

Lock

Values and Recommendations

Key Stats

Consensus Score

Lock

Recommendation

Lock

EPS 1 month Change

Lock

Quality Yield

Lock

Falling Divs over next 2

Lock

Halo Consensus Score

Lock Chart

PEG Ratio

Lock Chart

Consensus EPS Revisions

Lock Chart

Short selling

Key Stats

Percent of Issue

0.00%

Value ($M)

0

Prior Change

N/A

7 Day Change

N/A

1 Month Change

N/A

3 Month Change

N/A

Discover
Short-selling
Opportunities

Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.

ACR Shortsell

Frequently Asked Questions

The current share price of Acrux Limited (ACR:ASX) is AU$0.034.
The 52-week high share price for Acrux Limited (ACR:ASX) is AU$0.10.
The 52-week low share price for Acrux Limited (ACR:ASX)? is AU$0.03.
Acrux Limited (ACR:ASX) does not pay a dividend.
The last dividend payment of Acrux Limited (ACR:ASX) is AU$0.06.
Acrux Limited (ACR:ASX) has a franking level of 0.0%.
Acrux Limited (ACR:ASX) is classified in the Healthcare.
The current P/E ratio for Acrux Limited (ACR:ASX) is .
logo
Login
Company
Company
Important

Get the latest insights and hot tips delivered right to your inbox

App Store Google Play

HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.